The shares of Biocon, a biopharmaceutical business, dropped 6% to Rs 320.80 on Thursday’s BSE trading after the company revealed a second-quarter loss that was influenced by a deferred tax charge.
The company’s operating revenue climbed 3.7% to Rs 3,590.4 crore from Rs 3,462 crore in Q2 of FY24, despite the poor operational and financial results.
In Q2, the pharmaceutical company’s net profit fell 84.2% year-over-year (YoY) to Rs 27.1 crore, a significant decrease from the Rs 172 crore recorded in the same quarter of the prior fiscal year. The EBITDA margin dropped to 19% in Q2 from 21% in the same period previous year, indicating a decline in operational performance.
In the second quarter of this fiscal year, EBITDA at the operating level decreased 7.6% to Rs 685.5 crore from Rs 741.3 crore in the same period last year.
Based in Bengaluru, India, Biocon Limited is a biopharmaceutical business. Kiran Mazumdar-Shaw established it in 1978. The business produces generic active pharmaceutical ingredients (APIs), which are marketed in the US and Europe, among other nations.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice